Regeneron
Regeneron Pharmaceuticals, Inc., commonly referred to as Regeneron, is a leading biotechnology company headquartered in the United States. Founded in 1988, Regeneron has established itself as a pioneer in the development of innovative medicines, particularly in the fields of ophthalmology, oncology, and immunology. With a strong focus on research and development, Regeneron is renowned for its unique products, including EYLEA® for eye diseases and Dupixent® for various allergic conditions. The company’s commitment to scientific excellence has positioned it as a key player in the biopharmaceutical industry, achieving significant milestones such as the rapid development of treatments during public health emergencies. Regeneron continues to expand its global footprint, with major operations across North America and Europe, solidifying its reputation as a leader in advancing healthcare solutions.
DitchCarbon Score
How does Regeneron's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Regeneron's score of 56 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Regeneron's reported carbon emissions
In 2023, Regeneron reported total carbon emissions of approximately 972,376,000 kg CO2e, comprising 69,600,000 kg CO2e from Scope 1, 29,900,000 kg CO2e from Scope 2, and a significant 872,876,000 kg CO2e from Scope 3 emissions. This reflects a commitment to transparency in their emissions reporting across all three scopes. Regeneron has set ambitious reduction targets, aiming to decrease their combined Scope 1 and 2 greenhouse gas emissions per square meter by 30% by 2025, using a 2016 peak baseline as a reference point. This initiative underscores their focus on improving operational efficiency and reducing their carbon footprint. The company has consistently disclosed emissions data, with a notable increase in total emissions from 2022, which were approximately 814,916,000 kg CO2e. This highlights the ongoing challenges in managing emissions within the biopharmaceutical industry, where growth and sustainability must be balanced. Regeneron's commitment to addressing climate change is evident in their structured approach to emissions reduction and their proactive stance in reporting and transparency.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 39,400,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 25,300,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 288,800,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Regeneron is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
